Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

78
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

56
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
56
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

21
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
21
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

42.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
42.8K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.5K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic vaccination for chronic hepatitis B: why most vaccines failed and what may work.

Antiviral research·2026
Same author

<i>In Silico</i> Studies of the Hepatitis B Virus Polymerase: Efforts to Identify Novel Drug Binding Sites to Inhibit HBV Replication.

Missouri medicine·2026
Same author

CD16<sup>+</sup> γδ T cells and antibody-dependent cellular cytotoxicity: a new axis of immune control in hepatitis B virus infection?

Gut·2026
Same author

Searching for immune correlates in Lassa vaccine development - workshop report.

NPJ vaccines·2026
Same author

Hepatitis B virus ribonuclease H inhibitors: Coming of age?

Antiviral research·2026
Same author

Author Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues.

Nature immunology·2026

Related Experiment Video

Updated: Apr 26, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Host factor-targeted hepatitis B virus therapies.

Adam Gehring1, Antonio Bertoletti, John E Tavis

  • 1Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Mo., USA.

Intervirology
|July 19, 2014
PubMed
Summary

This review explores host factors targeting hepatitis B virus (HBV) replication. Novel therapeutic strategies aim to enhance viral clearance and reduce HBV burden when combined with existing treatments.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.8K

Related Experiment Videos

Last Updated: Apr 26, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.8K

Area of Science:

  • Hepatology and Virology
  • Immunology and Infectious Diseases

Background:

  • Hepatitis B virus (HBV) infection remains a significant global health challenge.
  • Current treatments, primarily nucleos(t)ide analogues, effectively suppress viral replication but do not achieve a complete cure.
  • Identifying host-directed therapeutic targets is crucial for developing novel strategies to eliminate HBV infection.

Purpose of the Study:

  • To review host factors that influence hepatitis B virus (HBV) replication.
  • To discuss current and potential therapeutic interventions targeting these host factors.
  • To explore novel avenues for reducing the HBV burden, potentially in combination with existing therapies.

Main Methods:

  • Literature review of studies on host-pathogen interactions in HBV infection.
  • Analysis of immunotherapeutic strategies and their potential for HBV clearance.
  • Examination of host machinery involved in HBV replication, including DNA silencing, RNA destabilization, and viral entry/trafficking.

Main Results:

  • Several host factors and cellular processes significantly impact HBV replication.
  • Immunotherapies show promise in activating interferon-mediated viral clearance.
  • Host machinery targeting viral DNA, RNA, entry, and trafficking are under early development.

Conclusions:

  • Host-directed therapies represent a promising frontier for managing HBV infection.
  • Targeting host factors can complement nucleos(t)ide analogues to achieve a greater reduction in HBV burden.
  • Further research and development are needed to translate these early-stage findings into effective clinical interventions.